#United States #New York #Leap Health #Hani Elias #Naguib Sawiris

Leap Experiences Remarkable Growth

Leap, recognized as a premier infusion therapy partner catering to self-funded employers, has reported an impressive 25-fold increase in its growth rate in 2025. This growth trajectory is complemented by the company’s strategic expansion of its leadership team, marked by the appointment of Hani Elias as the new Chief Executive Officer. Alongside him, co-founders Amir Sharif and Rob LaHayne move into new operational roles, while Naguib S. Sawiris is appointed as the Chairman of the Board.

This rapid expansion has allowed Leap to broaden its coverage to all 50 states, significantly growing its number of covered lives and producing validated savings of up to $3 million per 10,000 covered lives. Notably, the company has become instrumental in enhancing patient outcomes, which remains a core focus as healthcare costs rise.

Hani Elias, the newly appointed CEO, highlighted the complexities and inefficiencies clouding the specialty infusion market. Specialty drugs, though constituting less than 2% of total prescriptions issued, are responsible for a staggering 54% of the drug spending in the United States. The challenge lies primarily in the delivery settings, where outpatient departments of hospitals often implement drastic markups, inflating costs by as much as 400% for identical specialty therapies.